- Previous Close
1.1800 - Open
1.1152 - Bid 1.1000 x 100
- Ask 1.2300 x 100
- Day's Range
1.0500 - 1.1900 - 52 Week Range
1.0000 - 6.6600 - Volume
398,188 - Avg. Volume
1,668,944 - Market Cap (intraday)
6.246M - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-8.0300 - Earnings Date Mar 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
www.dermatarx.comRecent News: DRMA
View MorePerformance Overview: DRMA
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DRMA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DRMA
View MoreValuation Measures
Market Cap
6.41M
Enterprise Value
3.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.10
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-135.87%
Return on Equity (ttm)
-310.44%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.29M
Diluted EPS (ttm)
-8.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
3.16M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.65M